Published in Infect Immun on October 01, 2005
VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science (2015) 1.91
Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A (2008) 1.61
Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol (2011) 1.27
Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One (2008) 1.20
Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines (2007) 1.17
Mucosal vaccine adjuvants update. Clin Exp Vaccine Res (2012) 1.15
Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines (2012) 1.04
Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun (2010) 1.00
Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity. J Infect Dis (2011) 0.96
Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I). Glycobiology (2009) 0.96
Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect Immun (2006) 0.96
A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol (2006) 0.96
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol (2010) 0.95
Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur J Immunol (2012) 0.94
Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I). Clin Vaccine Immunol (2010) 0.91
Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT). J Biol Chem (2010) 0.87
Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev Vaccines (2009) 0.84
Mouse models for the study of mucosal vaccination against otitis media. Vaccine (2008) 0.83
PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens. J Immune Based Ther Vaccines (2010) 0.83
Enhancing the protective immune response against botulism. Infect Immun (2013) 0.81
Immunity to a self-derived, channel-forming peptide in the respiratory tract. Clin Vaccine Immunol (2007) 0.80
Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice. Clin Vaccine Immunol (2011) 0.79
Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. AIDS Res Hum Retroviruses (2014) 0.79
Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins. Mol Oral Microbiol (2011) 0.78
Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery. Toxins (Basel) (2014) 0.75
Nasal Administration of Cholera Toxin as a Mucosal Adjuvant Damages the Olfactory System in Mice. PLoS One (2015) 0.75
Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52
Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol (1997) 5.95
Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol (1984) 3.89
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine (1988) 3.00
Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol (1995) 2.87
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun (1988) 2.32
Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect Immun (1982) 2.08
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol (2000) 2.06
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun (1997) 2.05
Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest (1997) 1.98
Ganglioside structure dictates signal transduction by cholera toxin and association with caveolae-like membrane domains in polarized epithelia. J Cell Biol (1998) 1.90
Cloning of genes that encode a new heat-labile enterotoxin of Escherichia coli. J Bacteriol (1986) 1.77
Entry of cholera toxin into polarized human intestinal epithelial cells. Identification of an early brefeldin A sensitive event required for A1-peptide generation. J Clin Invest (1993) 1.69
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)-microglobulin-deficient BALB/c mice. J Exp Med (1996) 1.61
Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med (1997) 1.61
The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol (1991) 1.51
Purification and characterization of type II heat-labile enterotoxin of Escherichia coli. Infect Immun (1986) 1.51
Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand J Immunol (1997) 1.48
Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice. J Immunol (1996) 1.33
Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect Immun (1993) 1.31
The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine (1999) 1.28
Comparative morphometry of the nasal cavity in rats and mice. J Anat (1982) 1.27
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol (1998) 1.21
Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb Pathog (1994) 1.21
A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity. J Biol Chem (1990) 1.20
Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun (1998) 1.20
Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Infect Immun (2000) 1.19
Characterization of the receptor for cholera toxin and Escherichia coli heat-labile toxin in rabbit intestinal brush borders. Biochem J (1986) 1.17
Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine. Gastroenterology (1985) 1.17
Molecular genetic analysis of ganglioside GD1b-binding activity of Escherichia coli type IIa heat-labile enterotoxin by use of random and site-directed mutagenesis. Infect Immun (1992) 1.16
Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun (1997) 1.13
Cholera toxin-sensitive neurons in guinea pig submucosal plexus. Am J Physiol (1993) 1.13
Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain (2003) 1.12
Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology (1998) 1.11
Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine (1992) 1.10
Genetic control of the murine immune response to cholera toxin. J Immunol (1985) 1.08
Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity. FEBS Lett (1991) 1.05
A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis (2002) 1.03
Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun (1999) 1.02
Comparative aspects of nasal airway anatomy: relevance to inhalation toxicology. Toxicol Pathol (1991) 1.02
Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine (1996) 0.99
Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis (2000) 0.96
Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol (1999) 0.92
Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J Immunol (1999) 0.91
The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane. Vaccine (1991) 0.90
Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine (1998) 0.82
Animal models for intranasal drug delivery studies. A review article. Acta Pharm Nord (1990) 0.81
Host response to Escherichia coli heat-labile enterotoxin via two microvillus membrane receptors in the rat intestine. Infect Immun (1989) 0.81
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
A victory for science and common sense. Br Dent J (2006) 6.08
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science (2007) 4.90
Graphene plasmonics for tunable terahertz metamaterials. Nat Nanotechnol (2011) 4.20
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S A (2009) 2.77
Applying network theory to epidemics: control measures for Mycoplasma pneumoniae outbreaks. Emerg Infect Dis (2003) 2.30
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther (2008) 2.17
Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun (2006) 1.93
IL-1 family nomenclature. Nat Immunol (2010) 1.79
Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci U S A (2010) 1.67
Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J Virol (2009) 1.61
A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine (2002) 1.58
Understanding intestinal cysteamine bitartrate absorption. J Pediatr (2006) 1.57
The influence of a CYP1A2 polymorphism on the ergogenic effects of caffeine. J Int Soc Sports Nutr (2012) 1.53
Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect Immun (2003) 1.51
Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine (2010) 1.36
Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med (2006) 1.36
IFN-beta production by TLR4-stimulated innate immune cells is negatively regulated by GSK3-beta. J Immunol (2008) 1.36
Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol (2003) 1.34
Dependence of bacterial protein adhesins on toll-like receptors for proinflammatory cytokine induction. Clin Diagn Lab Immunol (2002) 1.31
Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem (2011) 1.31
Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem (2007) 1.27
Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities. Infect Immun (2005) 1.24
MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood (2002) 1.21
IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res (2003) 1.21
Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci U S A (2003) 1.19
The A subunit of type IIb enterotoxin (LT-IIb) suppresses the proinflammatory potential of the B subunit and its ability to recruit and interact with TLR2. J Immunol (2007) 1.18
Toll-like receptor 2 mediates cellular activation by the B subunits of type II heat-labile enterotoxins. Infect Immun (2005) 1.18
Counteracting interactions between lipopolysaccharide molecules with differential activation of toll-like receptors. Infect Immun (2002) 1.17
Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol (2011) 1.16
HIV infection: first battle decides the war. Trends Immunol (2006) 1.15
Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim Biophys Acta (2007) 1.15
The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells. Infect Immun (2004) 1.12
Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br J Clin Pharmacol (2007) 1.12
Invasive pneumococcal infections among vaccinated children in the United States. J Pediatr (2009) 1.10
Ganglioside GD1a is an essential coreceptor for Toll-like receptor 2 signaling in response to the B subunit of type IIb enterotoxin. J Biol Chem (2007) 1.10
Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. J Immunol (2003) 1.09
Role of gut-associated lymphoreticular tissues in antigen-specific intestinal IgA immunity. J Immunol (2004) 1.08
Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses. Infect Immun (2005) 1.07
Hop tests correlate with IKDC and KOOS at minimum of 2 years after primary ACL reconstruction. Knee Surg Sports Traumatol Arthrosc (2011) 1.07
A selenium-based click AdoMet analogue for versatile substrate labeling with wild-type protein methyltransferases. Chembiochem (2012) 1.07
Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J Immunol (2009) 1.06
Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity. J Immunol (2004) 1.06
BhuR, a virulence-associated outer membrane protein of Bordetella avium, is required for the acquisition of iron from heme and hemoproteins. Infect Immun (2002) 1.05
A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine (2008) 1.05
Id2-, RORgammat-, and LTbetaR-independent initiation of lymphoid organogenesis in ocular immunity. J Exp Med (2009) 1.04
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol (2008) 1.04
Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines (2012) 1.04
Preferential use of DH reading frame 2 alters B cell development and antigen-specific antibody production. J Immunol (2008) 1.04
Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer. J Immunol (2009) 1.04
A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis (2002) 1.03
Inside the mucosal immune system. PLoS Biol (2012) 1.03
T helper type-2 cells induce ileal villus atrophy, goblet cell metaplasia, and wasting disease in T cell-deficient mice. Gastroenterology (2003) 1.02
The role of glycogen synthase kinase 3 in regulating IFN-β-mediated IL-10 production. J Immunol (2010) 1.02
Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect Immun (2005) 1.02
Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation. Eur J Immunol (2003) 1.01
Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology (2008) 1.00
Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol (2010) 0.99
Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine (2011) 0.99
Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect (2010) 0.99
Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol (2006) 0.97
A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J Immunol (2008) 0.97
Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J Immunol (2008) 0.97
Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction (2009) 0.96
Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J Immunol (2003) 0.96
Role of mitogen-activated protein kinases and NF-kappaB in the regulation of proinflammatory and anti-inflammatory cytokines by Porphyromonas gingivalis hemagglutinin B. Infect Immun (2005) 0.96
Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect Immun (2006) 0.96
Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I). Glycobiology (2009) 0.96
A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol (2006) 0.96
Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med (2007) 0.96
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther (2008) 0.95